Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Current Oncology (Toronto, Ont.)|December 31, 2020
Longitudinal health utilities, symptoms and toxicities in patients with ALK-rearranged lung cancer treated with tyrosine kinase inhibitors: a prospective real-world assessmentB C Tse, B I Said, Z J Fan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 30, 2025
Early and locally advanced non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†A Zer, M-J Ahn, F Barlesi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 8, 2017
Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trialR Hui, E B Garon, J W Goldman, et al.
Current Oncology (Toronto, Ont.)|May 12, 2017
Improving molecular testing and personalized medicine in non-small-cell lung cancer in OntarioC Lim, H S Sekhon, J C Cutz, et al.
European Journal of Cancer (Oxford, England : 1990)|December 12, 2018
Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trialsY Kanjanapan, D Day, M O Butler, et al.
Lung Cancer (Amsterdam, Netherlands)|May 30, 2021
A phase I study of binimetinib (MEK 162), a MEK inhibitor, plus carboplatin and pemetrexed chemotherapy in non-squamous non-small cell lung cancerA S Fung, D M Graham, E X Chen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 6, 2021
Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancerA J Schoenfeld, S J Antonia, M M Awad, et al.
Current Oncology (Toronto, Ont.)|September 25, 2019
Crizotinib inhibition of ROS1-positive tumours in advanced non-small-cell lung cancer: a Canadian perspectiveD G Bebb, J Agulnik, R Albadine, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 16, 2024
Lung cancer research and treatment: global perspectives and strategic calls to actionM-L Meyer, S Peters, T S Mok, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 19, 2026
ESMO Adaptation of Lines of Systemic Therapy (EnLiST): a consensus framework for standardising the designation of lines of therapy in solid tumoursK S Saini, M Koopman, D Martins-Branco, et al.
Pageof 5